Oncology

Parents who know about the human papillomavirus are not more likely to get their adolescent daughters vaccinated.

Patients who smoke both traditional and e-cigarettes less likely to quit than those who only smoke traditional cigarettes.

Study finds stringent eligibility criteria is creating a barrier for patient enrollment.

A new metaanalysis suggests that quitting smoking, or even reducing tobacco intake, reduces the risk of dying from prostate cancer.

Therapy significantly reduces development of secondary skin cancer.

A combination of vemurafenib (Zelboraf) and experimental drug cobimetinib significantly reduces the development of secondary skin cancer.

The results of an FDA safety review of omalizumab (Xolair) suggest the asthma drug slightly elevates the risk of serious cardiovascular and cerebrovascular adverse events.

A combination of Lactobacillus plantarum and a modified inulin derivative reduced expression of T-cells in mammary cancers induced in rats.

A recent metaanalysis suggests that prediabetes increases the risk of developing certain cancers, particularly in tissues located near the gastrointestinal tract.

RX-3117 maintains anti-tumor activity in cancer cell lines that are resistant to gemcitabine.

Researchers in Japan are beginning to construct patient-centered counseling techniques for breast cancer by evaluating patient preference.

Amgen has submitted a new drug application to the FDA for its novel leukemia candidate, blinatumomab.

One major challenge in breast cancer is determining which treatment will be most effective for an individual patient's tumor. With a genetic panel, the TAXSig system may help change that.

Protein found to play vital role in development of disease.

Researchers find 23 new prostate cancer risk sites on the genome.

Baldness on front and crown of head linked to increased chance of developing aggressive prostate cancer.

A prognostic disease marker that often occurs in patients with triple-negative breast cancer may lead to development of a medication to close a therapeutic gap in targeted cancer treatment.

The FDA has expanded the approval for enzalutamide (Xtandi) to include the treatment of men with chemotherapy-naive metastatic castration-resistant prostate cancer.

For patients, having many treatment options can add to the stress of a cancer diagnosis.

Regina, a licensed pharmacist for more than 20 years, developed breast cancer at 48 years of age.

A recent meta-analysis published in the journal Plos One indicates a potential link between breast cancer and use of a common blood pressure medication, but a closer look tells a different story.

Pembrolizumab is the first drug approved that blocks the PD-1 cellular pathway.